{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:42:16Z","timestamp":1765888936234,"version":"build-2065373602"},"reference-count":105,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hemophilia of Georgia","award":["K08 HL102162","K08 HL151962","U54 HL141981"],"award-info":[{"award-number":["K08 HL102162","K08 HL151962","U54 HL141981"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health National Heart, Lung, and Blood Institute grants","doi-asserted-by":"publisher","award":["K08 HL102162","K08 HL151962","U54 HL141981"],"award-info":[{"award-number":["K08 HL102162","K08 HL151962","U54 HL141981"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"2018 HTRS\/Novo Nordisk Mentored Research Award","award":["K08 HL102162","K08 HL151962","U54 HL141981"],"award-info":[{"award-number":["K08 HL102162","K08 HL151962","U54 HL141981"]}]},{"name":"Novo Nordisk Inc.","award":["K08 HL102162","K08 HL151962","U54 HL141981"],"award-info":[{"award-number":["K08 HL102162","K08 HL151962","U54 HL141981"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The development of anti-drug antibodies represents a significant barrier to the utilization of protein-based therapies for a wide variety of diseases. While the rate of antibody formation can vary depending on the therapeutic employed and the target patient population receiving the drug, the antigen-specific immune response underlying the development of anti-drug antibodies often remains difficult to define. This is especially true for patients with hemophilia A who, following exposure, develop antibodies against the coagulation factor, factor VIII (FVIII). Models capable of studying this response in an antigen-specific manner have been lacking. To overcome this challenge, we engineered FVIII to contain a peptide (323\u2013339) from the model antigen ovalbumin (OVA), a very common tool used to study antigen-specific immunity. FVIII with an OVA peptide (FVIII-OVA) retained clotting activity and possessed the ability to activate CD4 T cells specific to OVA323\u2013339 in vitro. When compared to FVIII alone, FVIII-OVA also exhibited a similar level of immunogenicity, suggesting that the presence of OVA323\u2013339 does not substantially alter the anti-FVIII immune response. Intriguingly, while little CD4 T cell response could be observed following exposure to FVIII-OVA alone, inclusion of anti-FVIII antibodies, recently shown to favorably modulate anti-FVIII immune responses, significantly enhanced CD4 T cell activation following FVIII-OVA exposure. These results demonstrate that model antigens can be incorporated into a therapeutic protein to study antigen-specific responses and more specifically that the CD4 T cell response to FVIII-OVA can be augmented by pre-existing anti-FVIII antibodies.<\/jats:p>","DOI":"10.3390\/biomedicines10071724","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T03:41:33Z","timestamp":1658115693000},"page":"1724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Engineering a Therapeutic Protein to Enhance the Study of Anti-Drug Immunity"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3675-2725","authenticated-orcid":false,"given":"Patricia E.","family":"Zerra","sequence":"first","affiliation":[{"name":"Center for Transfusion Medicine and Cellular Therapies, Department of Laboratory Medicine and Pathology, Emory University, Atlanta, GA 30322, USA"},{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest T.","family":"Parker","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wallace Hunter","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Healey","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"McCoy","sequence":"additional","affiliation":[{"name":"Center for Transfusion Medicine and Cellular Therapies, Department of Laboratory Medicine and Pathology, Emory University, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Cox","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean R.","family":"Stowell","sequence":"additional","affiliation":[{"name":"Joint Program in Transfusion Medicine, Department of Pathology, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon L.","family":"Meeks","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"ref_1","first-page":"CD009806","article-title":"Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI","volume":"9","author":"Brunelli","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_2","first-page":"CD011539","article-title":"Enzyme replacement therapy for infantile-onset Pompe disease","volume":"11","author":"Chen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3928\/19382359-20180424-01","article-title":"Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases","volume":"47","author":"Li","year":"2018","journal-title":"Pediatr. Ann."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2174\/1389201018666170808150742","article-title":"Therapeutic Enzymes: Applications and Approaches to Pharmacological Improvement","volume":"18","author":"Yari","year":"2017","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2040620717721458","article-title":"Current and emerging factor VIII replacement products for hemophilia A","volume":"8","author":"Cafuir","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: Diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Fernandez-Pereira, C., San Millan-Tejado, B., Gallardo-Gomez, M., Perez-Marquez, T., Alves-Villar, M., Melcon-Crespo, C., Fernandez-Martin, J., and Ortolano, S. (2021). Therapeutic Approaches in Lysosomal Storage Diseases. Biomolecules, 11.","DOI":"10.3390\/biom11121775"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02982558","article-title":"Upshaw-Schulman syndrome revisited: A concept of congenital thrombotic thrombocytopenic purpura","volume":"74","author":"Kinoshita","year":"2001","journal-title":"Int. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: Systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2796.2007.01855.x","article-title":"Immune tolerance: Mechanisms and application in clinical transplantation","volume":"262","author":"Sykes","year":"2007","journal-title":"J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.anai.2020.07.010","article-title":"Management of hypersensitivity reactions to enzyme replacement therapy in children with lysosomal storage diseases","volume":"125","author":"Toyran","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2516.1999.t01-1-00303.x","article-title":"Anaphylactic response to factor IX replacement therapy in haemophilia B patients: Complete gene deletions confer the highest risk","volume":"5","author":"Thorland","year":"1999","journal-title":"Haemophilia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies","volume":"11","author":"DeKosky","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ijlh.12659","article-title":"Factor VIII inhibitors: Advances in basic and translational science","volume":"39","author":"Lai","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_16","first-page":"223","article-title":"Emicizumab for the treatment of haemophilia A: A narrative review","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"Kempton","year":"2014","journal-title":"Blood"},{"key":"ref_19","first-page":"143","article-title":"Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET","volume":"18","author":"Castaman","year":"2020","journal-title":"Blood Transfus."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","article-title":"Advances in the management of haemophilia: Emerging treatments and their mechanisms","volume":"28","author":"Okaygoun","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40263-022-00920-6","article-title":"Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis","volume":"36","author":"Sorensen","year":"2022","journal-title":"CNS Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2516.2008.01711.x","article-title":"Inhibitor development","volume":"14","author":"Astermark","year":"2008","journal-title":"Haemophilia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17474086.2020.1739518","article-title":"Patients with hemophilia A and inhibitors: Prevention and evolving treatment paradigms","volume":"13","author":"Lillicrap","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.transci.2018.07.012","article-title":"The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A","volume":"57","author":"Kevane","year":"2018","journal-title":"Transfus. Apher. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood.2021015370","article-title":"Shortage of plasma-derived products: A looming crisis?","volume":"139","author":"Covington","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/trf.16435","article-title":"Are we forgetting about IgA? A re-examination of COVID-19 convalescent plasma","volume":"61","author":"Verkerke","year":"2021","journal-title":"Transfusion"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e02026-20","DOI":"10.1128\/JCM.02026-20","article-title":"Comparison of Antibody Class Specific SARS-CoV-2 Serology for the Diagnosis of Acute COVID-19","volume":"59","author":"Verkerke","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0140-6736(92)90530-G","article-title":"Factor VIII inhibitors in haemophiliacs","volume":"340","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia A patient with a factor VIII inhibitor","volume":"113","author":"Kempton","year":"2009","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"Ehrenforth","year":"1992","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1182\/blood-2007-06-096842","article-title":"Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation","volume":"110","author":"Meeks","year":"2007","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1538-7836.2004.00944.x","article-title":"Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity","volume":"2","author":"Aledort","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1538-7836.2004.00802.x","article-title":"Pathogenic antibodies to coagulation factors. Part one: Factor VIII and factor IX","volume":"2","author":"Lollar","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/j.1538-7836.2005.01375.x","article-title":"Cellular immune responses in hemophilia: Why do inhibitors develop in some, but not all hemophiliacs?","volume":"3","author":"White","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02828.x","article-title":"Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age","volume":"113","author":"Lorenzo","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/hae.13641","article-title":"Emicizumab: Review of the literature and critical appraisal","volume":"25","author":"Valentino","year":"2019","journal-title":"Haemophilia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/JBM.S175952","article-title":"Spotlight on emicizumab in the management of hemophilia A: Patient selection and special considerations","volume":"10","author":"Yada","year":"2019","journal-title":"J. Blood Med."},{"key":"ref_39","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/j.1538-7836.2009.03571.x","article-title":"Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A","volume":"7","author":"Navarrete","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2017-05-782912","article-title":"Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A","volume":"130","author":"Zerra","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3324\/haematol.2017.165720","article-title":"Complement C3 is a novel modulator of the anti-factor VIII immune response","volume":"103","author":"Rayes","year":"2018","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/bloodadvances.2018018556","article-title":"Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo","volume":"2","author":"Parvathaneni","year":"2018","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3389\/fimmu.2019.00274","article-title":"Reprogrammed CD4(+) T Cells That Express FoxP3(+) Control Inhibitory Antibody Formation in Hemophilia A Mice","volume":"10","author":"Herzog","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"275ra221","DOI":"10.1126\/scitranslmed.aaa1957","article-title":"Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance","volume":"7","author":"Gupta","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: Immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood-2009-01-200725","article-title":"Lineages of human T-cell clones, including T helper 17\/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses","volume":"114","author":"Ettinger","year":"2009","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1160\/TH16-05-0404","article-title":"Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin","volume":"117","author":"Biswas","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/bloodadvances.2019000650","article-title":"Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice","volume":"3","author":"Jing","year":"2019","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"925135","DOI":"10.1155\/2012\/925135","article-title":"CD4(+)T cells: Differentiation and functions","volume":"2012","author":"Luckheeram","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.3389\/fimmu.2019.02138","article-title":"Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells","volume":"10","author":"Nguyen","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.clinthera.2019.08.010","article-title":"Mouse Models as Resources for Studying Infectious Diseases","volume":"41","author":"Sarkar","year":"2019","journal-title":"Clin. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Herati, R.S., and Wherry, E.J. (2018). What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Consideration of Strategies to Improve the Value of Animal Models. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a031583"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/febs.13612","article-title":"Preclinical modeling of hematopoietic stem cell transplantation\u2014Advantages and limitations","volume":"283","author":"Stolfi","year":"2016","journal-title":"FEBS J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1172\/JCI200317477","article-title":"Heterologous immunity provides a potent barrier to transplantation tolerance","volume":"111","author":"Adams","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Cho, Y.B., Lee, I.G., Joo, Y.H., Hong, S.H., and Seo, Y.J. (2020). TCR Transgenic Mice: A Valuable Tool for Studying Viral Immunopathogenesis Mechanisms. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249690"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.3389\/fimmu.2018.03039","article-title":"Relative Frequencies of Alloantigen-Specific Helper CD4 T Cells and B Cells Determine Mode of Antibody-Mediated Allograft Rejection","volume":"9","author":"Alsughayyir","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-0037-1615873","article-title":"CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects","volume":"82","author":"Reding","year":"1999","journal-title":"Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ajh.2830420408","article-title":"Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the Multi-Center Hemophilia Cohort Study","volume":"42","author":"Bray","year":"1993","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1182\/blood.2020009376","article-title":"Marginal zone B cells mediate a CD4 T-cell-dependent extrafollicular antibody response following RBC transfusion in mice","volume":"138","author":"Zerra","year":"2021","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1073\/pnas.79.14.4395","article-title":"Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions","volume":"79","author":"Meuer","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0198-8859(97)00078-5","article-title":"Antigen presentation by MHC class II molecules: Invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture","volume":"54","author":"Castellino","year":"1997","journal-title":"Hum. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O","article-title":"Virus-specific MHC-class II-restricted TCR-transgenic mice: Effects on humoral and cellular immune responses after viral infection","volume":"28","author":"Oxenius","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1046\/j.1440-1711.1998.00709.x","article-title":"Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements","volume":"76","author":"Barnden","year":"1998","journal-title":"Immunol. Cell Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.ymthe.2017.07.012","article-title":"Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations","volume":"25","author":"Wingerath","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1046\/j.1600-6135.2003.00246.x","article-title":"Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection","volume":"3","author":"Ehst","year":"2003","journal-title":"Am. J. Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00281-015-0477-5","article-title":"Listeria monocytogenes: A model pathogen to study antigen-specific memory CD8 T cell responses","volume":"37","author":"Khan","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood-2009-04-214387","article-title":"Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model","volume":"114","author":"Desmarets","year":"2009","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1016\/S0021-9258(17)37014-X","article-title":"Elimination of a major inhibitor epitope in factor VIII","volume":"269","author":"Lubin","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V95.2.564","article-title":"Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human\/porcine factor VIII molecules","volume":"95","author":"Barrow","year":"2000","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood.V92.10.3701","article-title":"Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII","volume":"92","author":"Healey","year":"1998","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/hae.12421","article-title":"Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: Implications for the immunogenicity of factor VIII","volume":"20","author":"Grushin","year":"2014","journal-title":"Haemophilia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1055\/s-0037-1613237","article-title":"Expression and characterization of recombinant murine factor VIII","volume":"88","author":"Doering","year":"2002","journal-title":"Thromb. Haemost."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1089\/10430340050015491","article-title":"Partial correction of murine hemophilia A with neo-antigenic murine factor VIII","volume":"11","author":"Sarkar","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jth.13202","article-title":"Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene","volume":"14","author":"Chao","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.2020009210","article-title":"Nonhuman glycans can regulate anti-factor VIII antibody formation in mice","volume":"139","author":"Arthur","year":"2022","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e121631","DOI":"10.1172\/jci.insight.121631","article-title":"Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses","volume":"3","author":"Mener","year":"2018","journal-title":"JCI Insight"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2017010124","article-title":"Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice","volume":"2","author":"Patel","year":"2018","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/trf.14939","article-title":"Antibody-mediated immunosuppression can result from RBC antigen loss independent of Fcgamma receptors in mice","volume":"59","author":"Mener","year":"2019","journal-title":"Transfusion"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"905","DOI":"10.3389\/fimmu.2020.00905","article-title":"Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation","volume":"11","author":"Zerra","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2018018408","article-title":"Antibody-mediated immune suppression by antigen modulation is antigen-specific","volume":"2","author":"Maier","year":"2018","journal-title":"Blood Adv."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.4049\/jimmunol.1300885","article-title":"Antigen modulation confers protection to red blood cells from antibody through Fcgamma receptor ligation","volume":"191","author":"Stowell","year":"2013","journal-title":"J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3389\/fimmu.2018.02516","article-title":"Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion","volume":"9","author":"Patel","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fimmu.2018.00676","article-title":"Complement Component 3 Negatively Regulates Antibody Response by Modulation of Red Blood Cell Antigen","volume":"9","author":"Mener","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1084\/jem.20151720","article-title":"Bridging channel dendritic cells induce immunity to transfused red blood cells","volume":"213","author":"Calabro","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4049\/jimmunol.2100784","article-title":"Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88","volume":"208","author":"Soldatenko","year":"2022","journal-title":"J. Immunol."},{"key":"ref_87","first-page":"612","article-title":"Proceedings: A more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb. Diath. Haemorrh."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1182\/blood-2012-02-412361","article-title":"A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function","volume":"120","author":"Meeks","year":"2012","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/j.1538-7836.2006.02135.x","article-title":"Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII","volume":"4","author":"Barrow","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.94.22.11851","article-title":"Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa","volume":"94","author":"Pipe","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1073\/pnas.85.8.2429","article-title":"Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII)","volume":"85","author":"Pittman","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.2016.148502","article-title":"The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells","volume":"102","author":"Gangadharan","year":"2017","journal-title":"Haematologica"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood-2019-127436","article-title":"Epitope dependent augmentation of the immune response in hemophilia A mice immunized with factor VIII\/antibody immune complexes","volume":"134","author":"Batsuli","year":"2019","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0952-7915(00)00191-6","article-title":"Danger signals: SOS to the immune system","volume":"13","author":"Gallucci","year":"2001","journal-title":"Curr. Opin. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: A renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1034\/j.1600-065X.2000.917309.x","article-title":"Innate immune recognition: Mechanisms and pathways","volume":"173","author":"Medzhitov","year":"2000","journal-title":"Immunol. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/35021228","article-title":"Toll-like receptors in the induction of the innate immune response","volume":"406","author":"Aderem","year":"2000","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/eji.200424916","article-title":"Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator","volume":"34","author":"Andersson","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd1176","article-title":"Recent advances in the discovery and delivery of vaccine adjuvants","volume":"2","author":"Valiante","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/SQB.1989.054.01.003","article-title":"Approaching the asymptote? Evolution and revolution in immunology","volume":"54","author":"Janeway","year":"1989","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","article-title":"Immunogenicity of protein therapeutics","volume":"28","author":"Scott","year":"2007","journal-title":"Trends Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3324\/haematol.2014.112821","article-title":"Alloantibodies to therapeutic factor VIII in hemophilia A: The role of von Willebrand factor in regulating factor VIII immunogenicity","volume":"100","author":"Oldenburg","year":"2015","journal-title":"Haematologica"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:52:39Z","timestamp":1760140359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/7\/1724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":105,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["biomedicines10071724"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10071724","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2022,7,18]]}}}